Πλοήγηση ανά Θέμα "canakinumab"
Αποτελέσματα 1-6 από 6
-
A critical appraisal of the pharmacological management of stable angina
(2021)The once dominant plaque-centric model of the pathophysiology and management of coronary artery disease (CAD) has long been questioned by a bulk of experimental and clinical evidence suggesting, among others, that coronary ... -
Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach
(2022)Available drugs have been used as an urgent attempt through clinical trials to minimize severe cases of hospitalizations with Coronavirus disease (COVID-19), however, there are limited data on common pharmacogenomics ... -
The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: The Greek experience in 12 patients
(2015)[No abstract available] -
Longterm beneficial effect of canakinumab in colchicine-resistant familial mediterranean fever
(2017)Objective. To assess the efficacy and safety of the interleukin-1β (IL-1β) inhibitor canakinumab in all adolescent and adult patients with familial Mediterranean fever (FMF) identified from the Greek National Registry for ... -
Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients
(2021)Objective: To assess the efficacy and safety of the IL-1b inhibitor canakinumab in all adults with refractory Still's disease identified from the National Organization For Medicines for off-label drug use. Methods -
Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition
(2017)Generalized pustular psoriasis (GPP) is a severe type of psoriasis accompanied by systemic and often life-threatening manifestations. The efficacy of the interleukin (IL)-1 antagonist anakinra in cases of GPP underscores ...